Agennix AG / Agennix AG Schedules Conference Call on March 24, 2010 to Discuss Year-End 2009 Financial Results processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 

Martinsried/Munich  (Germany), Princeton,  NJ and  Houston, TX, March 22, 2010 -
Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company will
hold a conference call to discuss financial results for the fiscal year 2009 and
to provide a business update. The results will be published on March 24, 2010 in
advance of the conference call.



The  conference  call,  which  will  be  conducted  in  English, will be held on
Wednesday, March 24, 2010 at 2 PM CET/ 9 AM ET.



The live webcast will be available on the Agennix Web site at www.agennix.com. A
replay will be available via the Web site following the live event.



Dial-in numbers for the call are as follows:



Participants from Europe:        0049 (0)69 667775756

0044 (0)20 3003 2666

Participants from the U.S.:       1-646-843-4608



Please dial in 10 minutes before the beginning of the meeting.



About Agennix

Agennix  AG is  a publicly  traded biopharmaceutical  company that is developing
novel  therapies in areas of major unmet  medical need to improve the length and
quality  of life of seriously ill  patients. The Company's most advanced program
is  talactoferrin, an  oral targeted  therapy that  has demonstrated activity in
randomized,  double-blind, placebo-controlled Phase  2 studies in non-small cell
lung  cancer as well as in severe sepsis. Talactoferrin is currently in Phase 3
clinical  trials  in  non-small  cell  lung  cancer.  Other clinical development
programs  include  RGB-286638,  a  multi-targeted  kinase  inhibitor in Phase 1
testing; the oral platinum-based compound satraplatin; and a topical gel form of
talactoferrin  for  diabetic  foot  ulcers.  Agennix's  registered  seat  is  in
Heidelberg,    Germany.    The   Company   has   three   sites   of   operation:
Martinsried/Munich,  Germany;  Princeton,  New  Jersey  and  Houston, Texas. For
additional information, please visit the Agennix Web site at www.agennix.com.



This  press  release  contains  forward-looking  statements,  which  express the
current  beliefs  and  expectations  of  the  management  of  Agennix  AG.  Such
statements  are  based  on  current  expectations  and  are subject to risks and
uncertainties,  many of  which are  beyond our  control, that could cause future
results,  performance or achievements to  differ significantly from the results,
performance  or  achievements  expressed  or  implied  by  such  forward-looking
statements.  Actual results  could differ  materially depending  on a  number of
factors,   and  we  caution  investors  not  to  place  undue  reliance  on  the
forward-looking  statements  contained  in  this  press release. Forward-looking
statements  speak  only  as  of  the  date  on  which  they are made and Agennix
undertakes no obligation to update these forward-looking statements, even if new
information becomes available in the future.



For further information, please contact:




Agennix
AG

Investor Relations & Corporate Communications

Phone: +49 (0)89
8565 2693

ir@agennix.com




In the U.S.: Laurie
Doyle

Director, Investor Relations & Corporate Communications

Phone: +1 609 524 5884


laurie.doyle@agennix.com






Additional media contacts for Europe:

MC Services
AG

Phone: +49 (0) 89 210 228 0



Raimund
Gabriel

raimund.gabriel@mc-services.eu




Hilda
Juhasz

hilda.juhasz@mc-services.eu





Additional investor contact for Europe:

Trout International
LLC

Lauren Williams, Vice President

Phone: +44 207 936 9325

lwilliams@troutgroup.com




[HUG#1395999]



 --- End of Message --- 

Agennix AG
Fraunhoferstr. 20 Martinsried Germany

ISIN: DE000A1A6XX4;
Listed: Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;